Therapy of advanced metastatic lung cancer with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience.

被引：0
|
作者：
Guarino, Michael J.
Starodub, Alexander
Masters, Gregory A.
Heist, Rebecca Suk
Messersmith, Wells A.
Bardia, Aditya
Ocean, Allyson J.
Thomas, Sajeve Samuel
Maliakal, Pius P.
Wegener, William A.
Sharkey, Robert M.
Wilhelm, Francois
Goldenberg, David M.
机构：
[1] Christiana Care Hlth Syst, Helen F Graham Canc Ctr, Newark, DE USA
[2] Indiana Univ Hlth, Goshen Ctr Canc Care, Goshen, IN USA
[3] Helen F Graham Canc Ctr, Newark, DE USA
[4] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA
[5] Univ Colorado Canc Ctr, Aurora, CO USA
[6] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA
[7] Weill Cornell Med Coll, New York, NY USA
[8] Univ Florida, Windermere, FL USA
[9] Immunomedics Inc, Morris Plains, NJ USA
[10] Garden State Canc Ctr, Ctr Mol Med & Immunol, Morris Plains, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.2504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2504
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2-metastatic breast cancer (mBC)
    Bardia, Aditya
    Diamond, Jennifer Robinson
    Vahdat, Linda T.
    Tolaney, Sara M.
    O'Shaughnessy, Joyce
    Moroose, Rebecca L.
    Mayer, Ingrid A.
    Abramson, Vandana Gupta
    Juric, Dejan
    Sharkey, Robert M.
    Washkowitz, Sarah A.
    Wegener, William A.
    Goldenberg, David M.
    Kalinsky, Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study.
    Tagawa, Scott T.
    Faltas, Bishoy Morris
    Lam, Elaine Tat
    Saylor, Philip James
    Bardia, Aditya
    Hajdenberg, Julio
    Morgans, Alicia K.
    Lim, Emerson A.
    Kalinsky, Kevin
    Simpson, Pamela S.
    Galsky, Matt D.
    Goswam, Trishna
    Wegener, William A.
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [33] Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan
    Goldenberg, David M.
    Sharkey, Robert M.
    MABS, 2019, 11 (06) : 987 - 995
  • [34] IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): Results from Phase I/II clinical trial (NCT01631552)
    Bardia, Aditya
    Starodub, Alexander
    Moroose, Rebecca L.
    Mayer, Ingrid A.
    Diamond, Jennifer R.
    Chuang, Ellen
    Govindan, Serengulam V.
    Sharkey, Robert M.
    Maliakal, Pius
    Wegener, William A.
    Hamburger, Steven A.
    Ocean, Allyson J.
    Goldenberg, David M.
    Vahdat, Linda T.
    CANCER RESEARCH, 2015, 75
  • [35] A Phase I study of IMMU-130 (labetuzumab-SN38) anti-CEACAM5 antibody-drug conjugate (ADC) in patients with metastatic colorectal cancer (mCRC).
    Segal, Neil H.
    Verghis, Jaclyn
    Govindan, Serengulam
    Maliakal, Pius
    Sharkey, Robert M.
    Wegener, William A.
    Goldenberg, David M.
    Saltz, Leonard B.
    CANCER RESEARCH, 2013, 73 (08)
  • [36] Safety and efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) as ≥3rd-line therapeutic option for treatment-refractory HER2-negative metastatic breast cancer (HER2Neg mBC)
    Kalinsky, K.
    Isakoff, S. J.
    Tolaney, S. M.
    Juric, D.
    Mayer, I. A.
    Vahdat, L. T.
    Diamond, J. R.
    O'Shaughnessy, J.
    Moroose, R. L.
    Santin, A. D.
    Shah, N. C.
    Abramson, V.
    Goldenberg, D. M.
    Sharkey, R. M.
    Washkowitz, S. A.
    Wegener, W. A.
    Iannone, R.
    Bardia, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [37] Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers
    Chang, Chien-Hsing
    Wang, Yang
    Zalath, Maria
    Liu, Donglin
    Cardillo, Thomas M.
    Goldenberg, David M.
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (08) : 1910 - 1919
  • [38] IMMU-132, a potential new antibody-drug conjugate (ADC) for the treatment of triple-negative breast cancer (TNBC): Preclinical and initial clinical results
    Goldenberg, David M.
    Vahdat, Linda T.
    Starodub, Alexander N.
    Bardia, Aditya
    Chuang, Ellen
    Moroose, Rebecca L.
    Diamond, Jennifer R.
    Sharkey, Robert M.
    Maliakal, Pius P.
    Hamburger, Steven A.
    Ocean, Allyson J.
    CANCER RESEARCH, 2015, 75
  • [39] Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer
    Dotan, Efrat
    Cohen, Steven J.
    Starodub, Alexander N.
    Lieu, Christopher H.
    Messersmith, Wells A.
    Simpson, Pamela S.
    Guarino, Michael J.
    Marshall, John L.
    Goldberg, Richard M.
    Hecht, J. Randolph
    Wegener, William A.
    Sharkey, Robert M.
    Govindan, Serengulam V.
    Goldenberg, David M.
    Berlin, Jordan D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (29) : 3338 - +
  • [40] Labetuzumab govitecan (IMMU-130), an anti-CEACAM5/SN-38 antibody-drug conjugate, is active in patients (pts) with heavily pretreated metastatic colorectal cancer (mCRC): phase II results
    Dotan, Efrat
    Cohen, Steven J.
    Starodub, Alexander N.
    Lieu, Christopher H.
    Messersmith, Wells A.
    Guarino, Michael J.
    Marshall, John L.
    Goldberg, Richard M.
    Hecht, J. Randolph
    Maliakal, Pius
    Wegener, William A.
    Sharkey, Robert M.
    Wilhelm, Francois
    Lee, Lucy
    Goldenberg, David M.
    Berlin, Jordan D.
    CANCER RESEARCH, 2016, 76
12345